London's AIM welcomes Arthro Kinetics:
This article was originally published in Clinica
Executive Summary
Stuttgart, Germany-based orthopaedics company Arthro Kinetics has begun trading its shares on the Alternative Investment Market at the London stock exchange, following the placement of nearly 5 million shares priced at 120p ($2.10) each. Some £6m was raised in total from the public offering, proceeds which will be used to complete US clinical trials of the firm's cartilage regeneration system, CaReS, and advance its product pipeline (see Clinica No 1195, p 15). The company's market capitalisation at the placing price is £33m.
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.